Recurrent CDC25C mutations drive malignant transformation in FPD/AML
Akihide Yoshimi(Memorial Sloan Kettering Cancer Center), Mineo Kurokawa(University of Tokyo Hospital)
Cited by 82
Related Papers
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
|Leukemia|2012|440
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
|Blood|2020|397
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
|Nature Medicine|2019|228
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
|Journal of Clinical Investigation|2014|216
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells
|Journal of Clinical Investigation|2013|197